Irbesartan Hydrochlorothiazide Accord-Uk (Hydrochlorothiazide, Irbesartan)

Irbesartan blocks the AT1 receptor for angiotensin II, preventing vasoconstriction and aldosterone‑mediated sodium retention. This leads to relaxation of blood vessels and reduced blood pressure. When paired with hydrochlorothiazide, which promotes sodium and water excretion, the overall effect is a synergistic reduction in vascular resistance and plasma volume.

The appropriate dose of Irbesartan Hydrochlorothiazide Accord-Uk is determined by the prescribing healthcare professional based on the patient’s clinical condition, response to therapy, and any relevant laboratory values. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Irbesartan Hydrochlorothiazide is classified as Pregnancy Category D, indicating evidence of fetal risk. It should be avoided during pregnancy. Limited data are available for breastfeeding; however, because the drug can be excreted in milk, it is generally not recommended for nursing mothers unless the benefit outweighs the risk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with monotherapy agents, the Irbesartan/Hydrochlorothiazide combination offers dual mechanisms—vascular relaxation from the ARB and volume reduction from the diuretic—often achieving better blood pressure control in patients who do not respond adequately to a single drug class. It may reduce the need for multiple separate tablets.

Store Irbesartan Hydrochlorothiazide Accord-Uk at ambient temperature, below 25 °C. Keep the tablets in the original container, protect them from moisture and direct light, and ensure the packaging remains tightly closed until use.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew it unless specifically instructed.

Serious risks include severe allergic reactions, acute kidney injury, hyperkalemia (high potassium levels), and marked hypotension that can cause fainting. Patients should seek immediate medical attention if they experience swelling, difficulty breathing, sudden loss of kidney function, or a drastic drop in blood pressure.

The product should be avoided in patients with known hypersensitivity to irbesartan, hydrochlorothiazide, or any component of the formulation. It is contraindicated in pregnancy, in individuals with severe renal impairment, and in those taking aliskiren concomitantly. Caution is also advised for patients with electrolyte disturbances or a history of angioedema.